Press releases

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA)...

BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue of $4.8 billion increased 1.5% as reported and...

Single Test on BD MAX™ Molecular Diagnostic System Identifies and Differentiates Multiple Respiratory Infectious Diseases FRANKLIN LAKES, N.J., Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson...

Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base...

Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and increased 2.3% on a currency-neutral basis Q4...

Diagnostic Research Center Enables Students to Test and Develop Clinical Workflows to Help Shape Laboratory Performance and Patient Outcomes FRANKLIN LAKES, N.J., Sept. 27, 2022 /PRNewswire/ -- BD...

Research Use Only (RUO) assay now globally available for BD MAX™ System FRANKLIN LAKES, N.J., Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

BD EffivaxTM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs...

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as...